Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 1 7 2020
medline: 18 1 2022
entrez: 30 6 2020
Statut: ppublish

Résumé

To investigate the presence of ethnic and socio-economic disparities in prostate cancer (PCa) screening and identify its impact on cancer outcomes. From January 2008 to December 2017, all men in the Northern region of New Zealand who had a prostate-specific antigen (PSA) test performed in the community were identified from the electronic laboratory reports database. Asymptomatic men, with no known diagnosis of PCa, were included. Variables collected were age, ethnicity, social deprivation, medical therapy, PSA test information and cancer data. Disparities were investigated by comparing the frequency of PSA testing, proportions of men screened, and rates of cancer detection, between Māori (indigenous) and non-Māori ethnic groups. The study cohort included 248 491 men, who each received approximately 3.45 PSA tests over the 10-year study period. Māori men were less likely to be tested compared to non-Māori men (25.4% vs 46.1% of the total aged-matched region population; P < 0.001). Moreover, they received less frequent PSA testing irrespective of their deprivation status (mean difference of 0.97 PSA tests per person; P < 0.001). The higher testing frequency in non-Māori men was associated with increased PCa diagnosis rates. Nevertheless, cancers detected in Māori men were 73% more likely to be of high grade (Gleason 8 or above), compared to those in non-Māori men. There were significant ethnic disparities in PCa screening rates in the Northern region of New Zealand. Māori men, regardless of other demographic factors, were disproportionately affected. The difference in the rates of screening by ethnicity had influenced the incidence and clinical significance of the diagnosed cancers.

Identifiants

pubmed: 32599662
doi: 10.1111/bju.15155
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-17

Informations de copyright

© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Références

Ministry of Health. Cancer: New Registrations and Deaths 2013. Wellington: Ministry of Health, 2016. Available at: https://www.health.govt.nz/publication/cancer-new-registrations-and-deaths-2013. Accessed November 2019
Ministry of Health. New Zealand Cancer Registry. New Cancer Registrations 2016. Wellington: Ministry of Health, 2018. Available at: https://www.health.govt.nz/publication/new-cancer-registrations-2016. Accessed November 2019
Costilla R, Tobias M, Blakely T. The burden of cancer in New Zealand: a comparison of incidence and DALY metrics and its relevance for ethnic disparities. Aust N Z J Public Health 2013; 37: 218-25
American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society, 2019. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. Accessed November 2019
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-71
Sneyd MJ. Ethnic differences in prostate cancer survival in New Zealand: a national study. Cancer Causes Control 2008; 19: 993-9
Obertova Z, Scott N, Brown C, Stewart A, Lawrenson R. Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand. BJU Int 2015; 115: 24-30
Australian Institute of Health and Welfare. Cancer in Aboriginal & Torres Strait Islander people of Australia. Canberra, ACT: Australian Institute of Health and Welfare, 2018. Available at: https://www.aihw.gov.au/reports/cancer/cancer-in-indigenous-australians. Accessed March 2020
Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011; 71: 985-97
Tewari A, Horninger W, Pelzer AE et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int 2005; 96: 1247-52
Tomic K, Ventimiglia E, Robinson D, Haggstrom C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer 2018; 142: 2478-84
Kilpelainen TP, Talala K, Raitanen J et al. Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer. Am J Epidemiol 2016; 184: 720-31
Best Practice Advocacy Centre (BPAC). Annual Practice Report Pharmaceutical and Laboratory Test Utilisation, 2014. Available at: https://bpac.org.nz/Report/2014/December/annRep.aspx. Accessed March 2019
Matti B, Zargar-Shoshtari K. Opportunistic prostate cancer screening: a population-based analysis. Urol Oncol 2020; 38: 393-400
Obertova Z, Scott N, Brown C et al. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand. BMC Fam Pract 2014; 15: 145
Prostate Cancer Working Group. Prostate Cancer Management and Referral Guidance. Wellington: Ministry of Health, 2015. Available at: https://www.health.govt.nz/publication/prostate-cancer-management-and-referral-guidance. Accessed March 2019
National Screening Advisory Committee. Prevalence of Opportunistic Prostate Cancer Screening in New Zealand. A report for the National Screening Advisory Committee. Wellington: Ministry of Health, 2010. Available at: https://www.health.govt.nz/publication/prevalence-opportunistic-prostate-cancer-screening-new-zealand. Accessed March 2019
Rundle A, Neckerman KM, Sheehan D et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. Cancer Cause Control 2013; 24: 297-303
Statistics New Zealand. 2013 Census Usually Resident Population Counts, 2013. Available at: http://archive.stats.govt.nz/Census/2013-census/data-tables.aspx. Accessed December 2018
Atkinson J, Salmond C, Crampton P. NZDep2013 Index of Deprivation. Wellington: Department of Public Health, University of Otago, 2014
Spencer BA, Babey SH, Etzioni DA et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer 2006; 106: 765-74
Jansen P, Bacal K, Crengle S. He Ritenga Whakaaro: Māori Experiences of Health Services. Auckland: Mauri Ora Associates, 2009. Available at: https://www.health.govt.nz/publication/he-ritenga-whakaaro-maori-experiences-health-services. Accessed January 2019
Willams PN, Gray MA, Ka'ai TM et al. Māori men's perceptions and experiences of health seeking for prostate health problems in New Zealand. Pac Health Dialog 2003; 10: 71-8
Patel MI, Kakala B, Beattie K. Teaching medical students digital rectal examination: a randomized study of simulated model vs rectal examination volunteers. BJU Int 2019; 124(S1): 14-8
Reynolds D. Prostate cancer screening in African American men: barriers and methods for improvement. Am J Mens Health 2008; 2: 172-7
Adams MJ, Collins VR, Dunne MP, de Kretser DM, Holden CA. Male reproductive health disorders among Aboriginal and Torres Strait Islander men: a hidden problem? Med J Aust 2013; 198: 33-8
Dean LT, Subramanian SV, Williams DR, Armstrong K, Zubrinsky Charles C, Kawachi I. Getting black men to undergo prostate cancer screening: the role of social capital. Am J Mens Health 2015; 9: 385-96
Tariq A, Khan SR, Vela I, Williams ED. Assessment of the use of the Internet and social media among people with bladder cancer and their carers, and the quality of available patient-centric online resources: a systematic review. BJU Int 2019; 123(S5): 10-8
Teh J, Op't Hoog S, Nzenza T et al. Penile cancer information on the internet: a needle in a haystack. BJU Int 2018; 122(S5): 22-6
Stanley J, Semper K, Millar E, Sarfati D. Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data. BMJ Open 2018; 8: e021689
Ministry of Health. Annual Data Explorer 2018/19: New Zealand Health Survey, 2019. Available at: https://minhealthnz.shinyapps.io/nz-health-survey-2018-19-annual-data-explorer/. Accessed March 2020
Jemal A, Fedewa SA, Ma J et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015; 314: 2054-61
Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
Hugosson J, Godtman RA, Carlsson SV et al. Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 2018; 52: 27-37
Bhardwaj A, Srivastava SK, Khan MA et al. Racial disparities in prostate cancer: a molecular perspective. Front Biosci 2017; 22: 772-82
Blair V, Kahokehr A, Sammour T. Cancer in Maori: lessons from prostate, colorectal and gastric cancer and progress in hereditary stomach cancer in New Zealand. ANZ J Surg 2013; 83: 42-8
Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
Van den Broeck T, van den Bergh RCN, Arfi N et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 2019; 75: 967-87
Zeps N, Davis ID, Mark S. Good clinical practice can and must include comparative effectiveness research. BJU Int 2018; 122(S5): 7-8
Scheltema MJ, Chang JI, Stricker PD et al. Diagnostic accuracy of 68Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68Ga-PSMA PET to mpMRI. BJU Int 2019; 124(S1): 42-9

Auteurs

Bashar Matti (B)

Department of Surgery, University of Auckland, Auckland, New Zealand.

Mataroria Lyndon (M)

Centre for Medical and Health Sciences Education, University of Auckland, Auckland, New Zealand.

Kamran Zargar-Shoshtari (K)

Department of Surgery, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH